SouthSeq, part of the Clinical Sequencing Evidence-Generating Research (<a href="https://www.genome.gov/Funded-Programs-Projects/Clinical-Sequencing-Evidence-Generating-Research-CSER2">CSER2</a>) effort, aims to perform genome sequencing for infants in nurseries at hospitals in Alabama, Mississippi, Louisiana, and Kentucky. SouthSeq aims to sequence 600 newborn babies presenting with congenital anomalies, or other signs of a rare genetic disorder. The primary goals of SouthSeq are to provide early diagnoses to children with rare genetic conditions, to demonstrate the utility of genome sequencing as a frontline test with potential to improve intermediate and long-term clinical outcomes, and to equip non-genetics providers to deliver test results in order to facilitate the conduction of genome sequencing outside of major medical centers where patients may not have access to a genetics provider. SouthSeq also aims to ensure that genomic testing is applied across diverse communities; recruitment efforts focus on patients from rural and minority populations that have been historically under-represented in both medicine and genomics research. 
Sequencing and analysis for SouthSeq are being conducted at the HudsonAlpha Institute for Biotechnology in Huntsville, Alabama (<a href="https://www.hudsonalpha.org/">https://www.hudsonalpha.org/</a>). Enrollment of infants with signs of genetic disease is approved at five clinical sites, including nurseries at the University of Alabama at Birmingham, the University of Mississippi Medical Center, Woman's Hospital in Baton Rouge, Children's Hospital in New Orleans, and the University of Louisville. Both biological parents are enrolled when available so that follow-up testing can be performed to determine inheritance. Further, participant families may choose to opt-into return of secondary findings identified in the proband, which focus on pathogenic and likely pathogenic variation identified within ACMG SFv3.0 genes.

ClinSeq is a pilot project to investigate the use of whole-genome sequencing as a tool for clinical research. By piloting the acquisition of large amounts of DNA sequence data from individual human subjects, we are fostering the development of hypothesis-generating approaches for performing research in genomic medicine, including the exploration of issues related to the genetic architecture of disease, implementation of genomic technology, informed consent, disclosure of genetic information, and archiving, analyzing, and displaying sequence data. In the initial phase of ClinSeq, we are enrolling roughly 1000 participants; the evaluation of each includes obtaining a detailed family and medical history, as well as a clinical evaluation. The participants are being consented broadly for research on many traits and for whole-genome sequencing. Initially, Sanger-based sequencing of 300-400 genes thought to be relevant to atherosclerosis is being performed, with the resulting data analyzed for rare, high-penetrance variants associated with specific clinical traits. The participants are also being consented to allow the contact of family members for additional studies of sequence variants to explore their potential association with specific phenotypes. Here, we present the general considerations in designing ClinSeq, preliminary results based on the generation of an initial 826 Mb of sequence data, the findings for several genes that serve as positive controls for the project, and our views about the potential implications of ClinSeq. The early experiences with ClinSeq illustrate how large-scale medical sequencing can be a practical, productive, and critical component of research in genomic medicine. Reprinted from Genome Res. 2009 Sep; 19(9): 1665-1674, with permission from Genome Research, PMID: <a href="http://www.ncbi.nlm.nih.gov/pubmed/19602640">19602640</a>.

Terra Workspace	Study	Consent Code	Disease (indication)	Data Type	Study Design	Participants
AnVIL_CSER_CHARM_GRU	Unspecified	GRU	Hereditary Cancer Risk	Whole Exome	Clinical Trial	827
AnVIL_CSER_NYCKIDSEQ_GRU	Unspecified	GRU	Suspected Genetic Disorder	2 data types	Clinical Trial	449
AnVIL_CSER_NCGENES2_GRU	Unspecified	GRU	Suspected Genetic Disorder	Whole Exome	Clinical Trial	100
AnVIL_CSER_KidsCanSeq_GRU	Unspecified	GRU	Cancer	2 data types	Case Set	623
AnVIL_CSER_NYCKIDSEQ_HMB	Unspecified	HMB	Suspected Genetic Disorder	2 data types	Clinical Trial	269
AnVIL_CSER_SouthSeq_GRU	CSER: South-Seq: DNA Sequencing for Newborn Nurseries in the South	GRU	Suspected Genetic Disorder	Whole Genome	Family/Twins/Trios	752
AnVIL_CSER_ClinSeq_GRU	The ClinSeq Project: Piloting Large-Scale Genome Sequencing for Research in Genomic Medicine	GRU	Healthy Adults	0	Case Set	0
AnVIL_CSER_P3EGS_GRU	CSER: Genomic Sequencing to Aid Diagnosis in Pediatric and Prenatal Practice: Examining Clinical Utility, Ethical Implications, Payer Coverage, and Data Integration in a Diverse Population	GRU	2 diseases	Whole Exome	2 study designs	534